Literature DB >> 23778723

Intratympanic gentamicin treatment 'as needed' for Meniere's disease. Long-term analysis using the Kaplan-Meier method.

Silvia Quaglieri1, Omar Gatti, Elisabetta Rebecchi, Marco Manfrin, Carmine Tinelli, Eugenio Mira, Marco Benazzo.   

Abstract

In recent years, several titration or on-demand protocols using low-dose repeated intratympanic (IT) gentamicin injections have been adopted for the vertigo control in unilateral medical refractory Menière's disease (MD). Because of the frequent recurrence and the need to treat the patients several times, it is difficult to strictly follow the 1995 AAO-HNS criteria to classify the results. The Kaplan-Meier analysis provides an effective and simpler method to address these concerns. We report the results of a long-term study (7 years) on a large population of MD patients (174) treated with on-request low-dose delayed IT gentamicin injections analysed using the Kaplan-Meier survival method. Effective vertigo control was obtained with a single injection in 40.2% of the patients (excellent responders) and with repeated injections (2-9) in 43.7% of the patients (moderate responders). Only six patients (3.5%) needed to be submitted to vestibular neurectomy because of the persistence of vertigo attacks (non-responders). A subgroup of 22 patients (12.6%) reporting a late recurrence of vertigo attacks after an initial vertigo-free interval lasting more than 2 years (short-term responders) were successfully treated with a further cycle of injections. In no cases, we observed significant signs of cochlear or vestibular toxicity. Kaplan-Meier survival analysis provided an excellent method for reporting treatment success or failure in patients followed for variable length of time with our kind of protocol.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23778723     DOI: 10.1007/s00405-013-2597-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  30 in total

Review 1.  Systematic review of intratympanic gentamicin in Meniere's disease.

Authors:  Chris Diamond; Daniel A O'Connell; Joshua D Hornig; Richard Liu
Journal:  J Otolaryngol       Date:  2003-12

2.  Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc.

Authors: 
Journal:  Otolaryngol Head Neck Surg       Date:  1995-09       Impact factor: 3.497

3.  Does intratympanic gadolinium injection predict efficacy of gentamicin partial chemolabyrinthectomy in Menière's disease patients?

Authors:  Gerd Claes; Luc Van den Hauwe; Floris Wuyts; Paul Van de Heyning
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-28       Impact factor: 2.503

Review 4.  Intratympanic gentamicin for Ménière's disease or syndrome.

Authors:  Bas Pullens; Peter Paul van Benthem
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

5.  Light microscopic evidence of hair cell regeneration after gentamicin toxicity in chick cochlea.

Authors:  R M Cruz; P R Lambert; E W Rubel
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-10

6.  Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy.

Authors:  L B Minor
Journal:  Am J Otol       Date:  1999-03

7.  Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease.

Authors:  Iee Ching Wu; Lloyd B Minor
Journal:  Laryngoscope       Date:  2003-05       Impact factor: 3.325

Review 8.  Outcomes of intratympanic gentamicin injection to treat Ménière's disease.

Authors:  Leh-Kiong Huon; Te-Yung Fang; Pa-Chun Wang
Journal:  Otol Neurotol       Date:  2012-07       Impact factor: 2.311

9.  Vestibular ototoxicity in the chick: effects of streptomycin on equilibrium and on ampullary dark cells.

Authors:  J C Park; G M Cohen
Journal:  Am J Otolaryngol       Date:  1982 Mar-Apr       Impact factor: 1.808

10.  Long-term vertigo control in patients after intratympanic gentamicin instillation for Ménière's disease.

Authors:  Daniel Bodmer; Sharon Morong; Craig Stewart; Ashlin Alexander; Joseph M Chen; Julian M Nedzelski
Journal:  Otol Neurotol       Date:  2007-12       Impact factor: 2.311

View more
  4 in total

1.  Modified titration intratympanic gentamicin injection for unilateral intractable Ménière's disease.

Authors:  Bo Liu; Yang-Ming Leng; Hong Shi; Ren-Hong Zhou; Jing-Jing Liu; Wen-Juan Zhang; Su-Lin Zhang; Wei-Jia Kong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  Vestibular and audiometric results after endolymphatic mastoid shunt surgery in patients with Menière's disease.

Authors:  Jennifer L Spiegel; Ivelina Stoycheva; Bernhard G Weiss; Mattis Bertlich; Tobias Rader; Martin Canis; Friedrich Ihler
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-15       Impact factor: 3.236

3.  Intratympanic Therapies for Menière's disease.

Authors:  Matthew W Miller; Yuri Agrawal
Journal:  Curr Otorhinolaryngol Rep       Date:  2014-09-01

4.  Low-Dose Intratympanic Gentamicin for Unilateral Ménière's Disease: Accuracy of Early Vestibulo-Ocular Reflex Gain Reduction in Predicting Long-Term Clinical Outcome.

Authors:  Ricardo Wegmann-Vicuña; Raquel Manrique-Huarte; Diego Calavia-Gil; Eduardo Martín-Sanz; Pedro Marques; Nicolas Perez-Fernandez
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.